The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.
CAR T cells
Hepatocellular carcinoma
T cells
TCR
adoptive cell transfer
immunotherapy
tumor immunology
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
08
2019
revised:
22
09
2019
accepted:
24
09
2019
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
1
2
2020
Statut:
epublish
Résumé
Hepatocellular Carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Current systemic therapies result only in modest benefits and new therapeutic options are critically needed. Some patients show promising clinical responses to immune checkpoint inhibitors, however, additional immunotherapeutic approaches, such as adoptive cell therapies (ACT), need to be developed. This review summarizes recent ACT studies and discusses the promise and obstacles of this approach. We further discuss ways of improving the efficacy of ACT in HCC including the use of combination therapies and locoregional delivery methods.
Identifiants
pubmed: 32002284
doi: 10.1080/2162402X.2019.1673129
pii: 1673129
pmc: PMC6959455
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1673129Informations de copyright
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Future Oncol. 2018 Sep;14(22):2293-2302
pubmed: 29663837
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 2015 Jul 15;21(14):3149-59
pubmed: 25850950
Cell. 2017 Feb 9;168(4):724-740
pubmed: 28187291
Lancet. 2000 Sep 2;356(9232):802-7
pubmed: 11022927
Hepatology. 2019 Feb;69(2):653-665
pubmed: 30102778
Cell Physiol Biochem. 2017;41(2):609-622
pubmed: 28214839
Cancer Immunol Immunother. 2018 Oct;67(10):1621-1634
pubmed: 30078052
Tumour Biol. 2016 Jan;37(1):799-806
pubmed: 26250457
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700
pubmed: 26484443
Oncogene. 2017 Mar;36(11):1476-1486
pubmed: 27775077
Science. 2017 Apr 14;356(6334):200-205
pubmed: 28408606
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802
pubmed: 22454499
Mol Ther. 2018 Nov 7;26(11):2542-2552
pubmed: 30415658
Cell Death Dis. 2018 Feb 15;9(3):282
pubmed: 29449531
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Cancer. 2016 Jun 1;122(11):1757-65
pubmed: 26998818
Hepatology. 2014 Apr;59(4):1415-26
pubmed: 24002931
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Gastroenterology. 2015 Oct;149(4):1042-52
pubmed: 26052074
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Clin Immunol. 2011 Jun;139(3):302-13
pubmed: 21419713
Hepatology. 1998 Feb;27(2):407-14
pubmed: 9462638
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Semin Radiat Oncol. 2018 Oct;28(4):332-341
pubmed: 30309643
Cancers (Basel). 2016 Nov 24;8(12):
pubmed: 27886124
Oncologist. 2019 Feb;24(Suppl 1):S3-S10
pubmed: 30819826
Sci Transl Med. 2014 Nov 5;6(261):261ra151
pubmed: 25378643
J Cell Physiol. 2019 Aug;234(8):12116-12121
pubmed: 30648254
Liver Cancer. 2016 Nov;6(1):1-12
pubmed: 27995082
Tumour Biol. 2017 Mar;39(3):1010428317692229
pubmed: 28347250
Clin Cancer Res. 2011 Jul 15;17(14):4719-30
pubmed: 21610146
Int J Cancer. 2018 May 1;142(9):1738-1747
pubmed: 29119551
J Immunol Res Ther. 2018;3(1):115-123
pubmed: 30123861
Oncol Res Treat. 2018;41(5):292-297
pubmed: 29705790
Oncotarget. 2015 Jun 30;6(18):15772-87
pubmed: 26158218
Trends Pharmacol Sci. 2016 Mar;37(3):220-230
pubmed: 26705086
Clin Cancer Res. 2018 Jan 1;24(1):95-105
pubmed: 29061641
Hepatology. 2018 Oct;68(4):1653-1655
pubmed: 29888796
Cancers (Basel). 2017 Jul 18;9(7):
pubmed: 28718815
Cancer Res. 2014 Dec 1;74(23):6796-805
pubmed: 25297631
Immunol Cell Biol. 2017 Apr;95(4):356-363
pubmed: 28003642
Am Soc Clin Oncol Educ Book. 2017;37:193-204
pubmed: 28561728
Cell Immunol. 2019 Feb;336:66-74
pubmed: 30626493
Breast Cancer Res Treat. 2014 May;145(1):23-32
pubmed: 24687377
N Engl J Med. 2008 Dec 4;359(23):2498; author reply 2498-9
pubmed: 19065701
Hepatology. 2018 Aug;68(2):574-589
pubmed: 29443377
Oncoimmunology. 2015 Mar 19;4(6):e1008354
pubmed: 26155416
Therap Adv Gastroenterol. 2017 Oct;10(10):805-814
pubmed: 29051790
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
Br J Cancer. 2015 Jun 9;112(12):1911-20
pubmed: 26057582
Ther Adv Med Oncol. 2019 Jul 23;11:1758835919862692
pubmed: 31384311
J Immunother. 2010 Feb-Mar;33(2):211-8
pubmed: 20139774
Immunotherapy. 2018 Apr;10(5):411-421
pubmed: 29473472
Front Pharmacol. 2018 Oct 01;9:1118
pubmed: 30327605
Protein Cell. 2017 Aug;8(8):573-589
pubmed: 28434147